PDE5A and COVID-19: Solaimanzadeh and coauthors [79] propose the use of PDE5 inhibitors, showing the analogy of COVID-19 to HAPE (high altitude pulmonary edema), a respiratory disease in which these molecules have already been clinically tested and used.